2015年2月6日讯/生物谷BIOON/--辉瑞近日宣布与Hospira达成收购协议，将以170亿美元收购Hospira，这也是辉瑞收购阿斯利康 未果后最大的一次收购行动。这桩收购是辉瑞加强其生物仿制药管线的重要举措。
Hospira股东将会获得每股90美元的现金，周三收盘时代表39%的溢价。交易结束后，将会为辉瑞带来10—12分美元的每股收益。
辉瑞收购Hospira后，将会加强其生物仿制药管线，获得此类药物专利时会帮助辉瑞处于更加有利的地位。过去辉瑞由于失去了很多专利保护权而丧失了大量的收益。
辉瑞的生物仿制药部门加强后，将会使辉瑞在财务方面获得极大的益处。据估计，仿制药比原创药的售价将会低20—30%左右。
此次收购将以现金和债务两种方式完成。据辉瑞称，这次收购将会为辉瑞在2018年之前每年节省约8亿美元的开支，预计这桩收购将于2015年下半年结束。
辉瑞周四盘前交易的股价上涨约3.21%。而Hospira的股价涨幅约35.34%，达到了每股87.7美元。
英文原文
Pfizer Inc. To Acquire Hospira (HSP) For $17 Billion
Pfizer Inc. (NYSE：PFE) is reported to have reached an agreement to acquire Hospira， Inc. (NYSE：HSP) in a $17 billion deal. The acquisition， announced on Thursday， comes as a result of Pfizer’s efforts to strengthen its biosimilar drug pipeline.
Hospira shareholders will receive around $90 in cash for every share， representing a 39% premium to the stock's closing price on Wednesday. The acquisition would have a positive impact of 10-12 cents to Pfizer’s earnings per share (EPS)， following the close of the deal.
Hospira's acquisition would strengthen the biosimilar pipeline at Pfizer， and give the company a better standing when getting patents for such drugs. In the past， Pfizer has lost substantial revenue due to lost patent protections.
A strengthened biosimilar drug development wing at Pfizer would also greatly benefit its financial statements. According to some estimates， biosimilar drugs cost 20-30% lower to develop than the original drugs.
The company will finance the deal with a combination of cash and debt. According to Pfizer， the agreement would lead to annual cost savings of around $800 million by 2018. The deal is expected to close in the second half of 2015.
Following the news， Pfizer stock is trading up by around 3.21% as of 8：28 AM EST during pre-market trading on Thursday. Hospira is trading up by around 35.34% at $87.7 per share.